TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01025232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Injection of 2.0mg formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Injection of 2.0mg formulation
Study: NCT02437968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camp Cope-A-Lot (Computer-assisted CBT program)
Description: Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camp Cope-A-Lot (Computer-assisted CBT program)
Description: Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Camp Cope-A-Lot (Computer-assisted CBT program)
Description: Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
Study: NCT02282891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of general anesthesia using propofol 2mg/kg
Study: NCT02497651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
Study: NCT02242916

Intervention type: RADIATION
Intervention: Photon therapy versus proton therapy

Intervention type: RADIATION
Intervention: Photon therapy versus C-ion therapy
Study: NCT00668161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
Study: NCT02066103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT00077857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda®)
Description: 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine (Xeloda®)
Description: 825 mg/m\^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere®)
Description: 75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Study: NCT03732235

Intervention type: DEVICE
Intervention: TACE+ systemic Bevacizumab
Description: PEG embolics
Study: NCT02282891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Ketamine
Description: Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
Study: NCT02103595

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink
Description: Insulin pump device used for 4-weeks under real life conditions

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink
Description: Insulin pump device used for 4-weeks under real life conditions

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink Plus
Description: Insulin pump device used for 4-weeks under real life conditions

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek FlexLink Plus
Description: Insulin pump device used for 4-weeks under real life conditions
Study: NCT03732235

Intervention type: DRUG
Intervention: FOLFIRI+Bevacizumab
Description: antiangiogenic factor

Intervention type: DEVICE
Intervention: TACE
Description: PEG embolics
Study: NCT04223206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NATURLENS
Description: Oral administration of dietary supplement (26 g/day) to dissolve in 100 or 150 mL of water
Study: NCT00540527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local interarterial recombinant tissue plasminogen activator
Description: Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) rt-PA
Description: IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
Study: NCT04437316

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Low level Laser after wisdom tooth removal
Description: Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Use of Low level Laser after wisdom tooth removal
Description: Directly after the wisdom teeth removal of the right/left side, one of the low level laser (therapeutic and non-therapeutic (Placebo)) is used.
Study: NCT01301404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10% carbohydrate drink
Description: In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
Study: NCT04130100

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose of Mesenchymal stem cell
Description: Mesenchymal stem cell injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose of Mesenchymal stem cell
Description: Mesenchymal stem cell injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate injection
Study: NCT01801124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: single dose 266 mg of undiluted EXPAREL
Study: NCT00850265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volumatic spacer
Description: A spacer is a plastic device to inhaler medication
Study: NCT04434261

Intervention type: DIAGNOSTIC_TEST
Intervention: PT-PCR test for SARS-CoV-2
Description: Screening test for the diagnosis of SARS-CoV-2 in asymptomatic patients
Study: NCT04416984

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ALLO-501A
Description: ALLO-501A is an allogeneic CAR T cell therapy targeting CD19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion
Study: NCT00741260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually
Study: NCT01594723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120 mg LY2784544
Description: Administered orally
Study: NCT03531073

Intervention type: DRUG
Intervention: Methotrexate
Description: This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
Study: NCT04167358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linerixibat
Description: All participants will receive linerixibat.
Study: NCT00741260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib orally once daily continually

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine orally on days 1-14 of each 21 day cycle
Study: NCT04262856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Study: NCT03771989

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous, micro-fragmented adipose tissue
Description: The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo is an injection with saline
Study: NCT02945839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preventative Medication (PM)
Description: Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications \< 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PMR (progressive muscle relaxation therapy)
Description: Technique for learning to monitor and control the state of muscular tension
Study: NCT05292573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: During the intervention period, metformin is given 500 mg tablet b.i.d. Those who stopped taking metformin will remain in the study not counting as protocol violation.
Study: NCT02506491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: 2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscular exercise
Description: 2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No exercise
Study: NCT02995473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP000888
Description: 270 µg/g topical (BID) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical (BID) for 24 weeks
Study: NCT03217175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bihormonal Bionic Pancreas
Description: The glucagon pump will be filled with glucagon during the exercise visit

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Only Bionic Pancreas
Description: The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
Study: NCT01900405

Intervention type: DRUG
Intervention: Dexmedetomidine
Study: NCT01510028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human arylsulfatase A
Description: 6 patients treated with HGT-1110 EOW by IT injection
Study: NCT00077857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (Taxotere®)
Description: 75 mg/m\^2 intravenous on day 1 of each 3 week cycle
Study: NCT00918840

Intervention type: BIOLOGICAL
Intervention: DermaVir
Description: DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: Dextrose/glucose solution
Study: NCT03217175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon will be given according to the algorithm in the bihormonal bionic pancreas

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
Study: NCT03102372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: walking program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking program
Study: NCT03102372

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Very Low Calorie Diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet
Study: NCT04454268

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cyst extirpation
Description: complete removal of the cyst without rupture
Study: NCT01510028

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human arylsulfatase A
Description: 6 patients treated with HGT-1110 EOW by IT injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human arylsulfatase A
Description: 6 patients treated with HGT-1110 EOW by IT injection
Study: NCT03006926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: 4 mg capsules
Study: NCT03598621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 0.5 mg/mL
Description: A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
Study: NCT03006926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (200 mg)
Description: 30-minute intravenous infusion
Study: NCT03892434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab and dexamethasone implant Injection
Description: Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab and dexamethasone implant Injection
Description: Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal dexamethasone implant
Description: Dexamethasone implant insertion using approved kit
Study: NCT01793090

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epi-743
Description: EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Placebo will be administered in the same formulation as the active comparator
Study: NCT01698177

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated trivalent vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Seasonal inactivated trivalent vaccine
Study: NCT00120510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine/Zidovudine
Description: Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
Study: NCT01122888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Given IV

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Observation
Description: Patients undergo a 2-week rest period
Study: NCT00918840

Intervention type: DRUG
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA

Intervention type: DRUG
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study: NCT00093873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-angiogenesis
Description: Anti-angiogenesis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: Anti-angiogenesis
Study: NCT03482700

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Arm
Description: The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Arm
Description: Usual standard of care
Study: NCT01147263

Intervention type: OTHER
Intervention: Evaluation of autonomic parameters
Description: Physical examination, ECG, Loop recorder, Heart rate variability evaluation
Study: NCT04262856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody